Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 73, Issue 5, 2005, Pages 405-410

  Di Renzo, M ^a   Pieragalli, D ^b   Meini, S ^b   De Franco, V ^b   Pompella, G ^a   Auteri, A ^b   Pasqui, A L ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; INTERLEUKIN 6; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROPIDIUM IODIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGED; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOTENSION; IN VIVO STUDY; LIMB ISCHEMIA; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; VASODILATATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; ILOPROST; INTERLEUKIN-6; ISCHEMIA; LOWER EXTREMITY; MALE; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25444496144     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2005.05.025     Document Type: Article

References (24)

1. R. Ross Atherosclerosis is an inflammatory disease N. Engl. J. Med. 340 1999 115 126
2. K. Schror Prostaciclin (Prostaglandin I2) and atherosclerosis G.M. Rubanyi V. Dzau The Endothelium in Clinical Practise: Source and Target of Novel Concepts and Therapies 1997 New York Marcel Dekker 1 44
3. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structures, properties and functions Physiol. Rev. 79 1999 1193 1226
4. T. Hatae, M. Wada, C. Yokoyama, M. Shimonishi, and T. Tanabe Prostacyclin-dependent apoptosis mediated by PPAR-δ J. Biol. Chem. 276 2001 46260 46267
5. H. Lim, and S.K. Dey Minireview: a novel pathway of prostacyclin signaling-Hanging out with nuclear receptors Endocrinology 143 2002 3207 3210
6. J. Meyer-Kirchrath, S. Debey, C. Gladorff, L. Kirchrath, and K. Schror Gene expression profile of the Gs-coupled prostcyclin receptor in human vascular smooth muscle cells Biochem. Pharmacol. 67 2004 757 765
7. A. Jorres, H. Dinter, N. Topley, G.M. Gahl, U. Frei, and P. Scholz Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms Cytokine 9 1997 119 125
8. E.G. Czeslick, A. Simm, S. Grond, R.E. Silber, and A. Sablotzki Inhibition of intracellular tumour necrosis factor alpha and interleukin-6 production in human monocytes by iloprost Eur. J. Clin. Invest. 33 2003 1013 1017
9. J.L. Young, P. Libby, and U. Schombeck Cytokines in the pathogenesis of atherosclerosis Thromb. Haemost. 88 2002 554 567
10. T. Kanda, and T. Takahashi Interleukin-6 and cardiovascular diseases Jpn. Heart J. 45 2004 183 193
11. A. Ceriello, M. Sardina, E. Motz, S. Lizzio, D. Tuniz, and C. Bianchini Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III Int. J. Ang. 7 1998 28 33
12. S. Meini, V. De Franco, A. Auteri, C. Setacci, M. Di Renzo, and D. Pieragalli Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischaemia patients (Leriche-Fontaine stage iii and iv) Int. Angiol. 24 2005 64 69
13. M. Hildebrand, and W. Krause Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis Int. J. Clin. Pharmacol. Res. 28 1990 285 292
14. T. Raff, M. Van Der Giet, D. Endemann, T. Wiederholt, and M. Paul Design and testing of β-actin primers for RT-PCR that do not coamplify processed psuedogenes Biotechniques 23 1997 456 460
15. P.K. Lund, E. Namork, and S. Henning Brorson The fate of monocytes during 24 h of culture as revealed by flow cytometry and electron microscopy J. Immunol. Methods 270 2002 63 76
16. T. Eisenhut, B. Sinha, E. Gottrup-Wolfers, J. Semmler, W. Siess, and S. Endres Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS stimulated human peripheral blood mononuclear cells Immunopharmacology 26 1993 259 264
17. G. Filaci, M. Cutolo, and M. Scudeletti Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy Rheumatology 38 1999 992 996
18. C.S. Holladay, R.M. Wright, and B.L. Spangelo Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro: evidence for a prostacyclin-dependent mechanism Prostaglandins Leukot. Essent. Fatty Acids 49 1993 915 922
19. N. Fiotti, C. Giansante, and E. Ponte Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease Atherosclerosis 145 1999 51 60
20. I.K. Gao, P. Scholz, M.W.J. Boehme, C. Norden, and E.M. Lemmel A 7-day oral treatment with active rheumatoid arthritis using the prostaciclin analog iloprost: cytokine modulation, safety, and clinical effects Rheumatol. Int. 22 2002 45 51
21. H. Hsu, J. Xiong, and D.V. Goeddel The TNF receptor-1 associated protein TRADD signals cell death and NF-kB activation Cell 81 1995 495 504
22. L.A. Tartaglia, and D.V. Goeddel Two TNF receptors Immunol. Today 13 1992 151 153
23. E. Douni, and G. Kollias A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation indipendent of TNF, lymphotoxin α, or the p55TNF-R J. Exp. Med. 188 1998 1343 1352
24. R. Lucas, I. Garcia, and Y.R.A. Donati Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells Eur. J. Immunol. 28 1998 3577 3586